1.Male and/or female patients aged â?¥ 18 and â?¤ 60 years of age (both inclusive). <br/ >2.Patients and LAR willing to comply with study protocol requirements and voluntarily able to provide written informed consent. <br/ >3.Patients with positive for SARS-CoV-2 confirmed by RT-PCR in nasopharyngeal and/or oropharyngeal swabs within 5 days prior to randomization. <br/ >4.Patients with uncomplicated upper respiratory tract symptoms may have one of the symptoms of fever, cough, sore throat, nasal congestion, malaise, headache or any other signs and COVID-19 symptoms without any evidence of breathlessness or hypoxia (normal saturation) within 5 days prior to the randomization. <br/ >5.Patients with a risk factor for progressing to severe COVID-19 (i.e., who have co-morbid conditions diabetes, hypertension and so on). <br/ >6.Male patients must agree to either abstain from sexual intercourse or to use contraception during the entire study duration and for a period of at least 04 days after the last dose of study medication or after the early withdrawal visit. <br/ >7.Female patients of childbearing potential must agree to either abstain from sexual intercourse or to use acceptable contraceptive method during the entire study duration and for a period of at least 04 days after the last dose of study medication or after the early withdrawal visit and must have negative urine pregnancy test prior to randomization. <br/ >Medically acceptable forms of contraceptive include: <br/ >a.Hormonal contraceptives (at least 1 month before screening visit) <br/ >b.Double barrier methods (e.g., diaphragm with spermicide, or condoms with spermicide) <br/ >c.Intrauterine device (IUD) <br/ >

1.Male and/or female patients aged â?¥ 18 and â?¤ 60 years of age (both inclusive). <br/ >2.Patients and LAR willing to comply with study protocol requirements and voluntarily able to provide written informed consent. <br/ >3.Patients with positive for SARS-CoV-2 confirmed by RT-PCR in nasopharyngeal and/or oropharyngeal swabs within 5 days prior to randomization. <br/ >4.Patients with uncomplicated upper respiratory tract symptoms may have one of the symptoms of fever, cough, sore throat, nasal congestion, malaise, headache or any other signs and COVID-19 symptoms without any evidence of breathlessness or hypoxia (normal saturation) within 5 days prior to the randomization. <br/ >5.Patients with a risk factor for progressing to severe COVID-19 (i.e., who have co-morbid conditions diabetes, hypertension and so on). <br/ >6.Male patients must agree to either abstain from sexual intercourse or to use contraception during the entire study duration and for a period of at least 04 days after the last dose of study medication or after the early withdrawal visit. <br/ >7.Female patients of childbearing potential must agree to either abstain from sexual intercourse or to use acceptable contraceptive method during the entire study duration and for a period of at least 04 days after the last dose of study medication or after the early withdrawal visit and must have negative urine pregnancy test prior to randomization. <br/ >Medically acceptable forms of contraceptive include: <br/ >a.Hormonal contraceptives (at least 1 month before screening visit) <br/ >b.Double barrier methods (e.g., diaphragm with spermicide, or condoms with spermicide) <br/ >c.Intrauterine device (IUD) <br/ >

1.Male and/or female patients aged â?¥ 18 and â?¤ 60 years of age (both inclusive). <br/ >2.Patients and LAR willing to comply with study protocol requirements and voluntarily able to provide written informed consent. <br/ >3.Patients with positive for SARS-CoV-2 confirmed by RT-PCR in nasopharyngeal and/or oropharyngeal swabs within 5 days prior to randomization. <br/ >4.Patients with uncomplicated upper respiratory tract symptoms may have one of the symptoms of fever, cough, sore throat, nasal congestion, malaise, headache or any other signs and COVID-19 symptoms without any evidence of breathlessness or hypoxia (normal saturation) within 5 days prior to the randomization. <br/ >5.Patients with a risk factor for progressing to severe COVID-19 (i.e., who have co-morbid conditions diabetes, hypertension and so on). <br/ >6.Male patients must agree to either abstain from sexual intercourse or to use contraception during the entire study duration and for a period of at least 04 days after the last dose of study medication or after the early withdrawal visit. <br/ >7.Female patients of childbearing potential must agree to either abstain from sexual intercourse or to use acceptable contraceptive method during the entire study duration and for a period of at least 04 days after the last dose of study medication or after the early withdrawal visit and must have negative urine pregnancy test prior to randomization. <br/ >Medically acceptable forms of contraceptive include: <br/ >a.Hormonal contraceptives (at least 1 month before screening visit) <br/ >b.Double barrier methods (e.g., diaphragm with spermicide, or condoms with spermicide) <br/ >c.Intrauterine device (IUD) <br/ >

1.Male and/or female patients aged â?¥ 18 and â?¤ 60 years of age (both inclusive). <br/ >2.Patients and LAR willing to comply with study protocol requirements and voluntarily able to provide written informed consent. <br/ >3.Patients with positive for SARS-CoV-2 confirmed by RT-PCR in nasopharyngeal and/or oropharyngeal swabs within 5 days prior to randomization. <br/ >4.Patients with uncomplicated upper respiratory tract symptoms may have one of the symptoms of fever, cough, sore throat, nasal congestion, malaise, headache or any other signs and COVID-19 symptoms without any evidence of breathlessness or hypoxia (normal saturation) within 5 days prior to the randomization. <br/ >5.Patients with a risk factor for progressing to severe COVID-19 (i.e., who have co-morbid conditions diabetes, hypertension and so on). <br/ >6.Male patients must agree to either abstain from sexual intercourse or to use contraception during the entire study duration and for a period of at least 04 days after the last dose of study medication or after the early withdrawal visit. <br/ >7.Female patients of childbearing potential must agree to either abstain from sexual intercourse or to use acceptable contraceptive method during the entire study duration and for a period of at least 04 days after the last dose of study medication or after the early withdrawal visit and must have negative urine pregnancy test prior to randomization. <br/ >Medically acceptable forms of contraceptive include: <br/ >a.Hormonal contraceptives (at least 1 month before screening visit) <br/ >b.Double barrier methods (e.g., diaphragm with spermicide, or condoms with spermicide) <br/ >c.Intrauterine device (IUD) <br/ >